{'fraction_non_alphanumeric': 0.03282442748091603, 'fraction_numerical': 0.0053435114503816794, 'mean_word_length': 4.724890829694323, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Does transfusion of Asian‐type DEL red blood cells to D– recipients cause D alloimmunization?

In 2005, the late George Garratty asked readers of TRANSFUSION, “Do we need to be more concerned about weak D antigens?”1 His question was prompted by his observation that “… there have been increasing numbers of reports of patients who had been transfused with donor blood having ‘weak D’ or undetectable D (e.g., DEL) who made anti-D.” Garratty reviewed the complexity of the D antigen and its variants, case reports of anti-D after transfusion of weak D RBCs to D- recipients, and variable D typing results depending on selection of anti-D reagents. He noted that most available data were from Europe and concluded that “countries with larger Asian or African populations … need to relate to statistics in their own countries.”1 Garratty’s question can be answered only when data are available for the many different scenarios in which different categories of weak D RBCs have been transfused to D- recipients. In this commentary, we address one of these scenarios, namely, the potential risk of D alloimmunization when Asian-type DEL (RHD*DEL1) RBCs are transfused to D- recipients in the United States. We suggest how this issue can be resolved by a focused study in pertinent communities in the United States.